According to Invima, this medication is also promoted for autoimmune diseases.
He National Institute for Food and Drug Surveillance (Invima) set off the alarms after issuing a health alert due to the circulation of a counterfeit medicine used to treat cancer and diseases of the immune system.
The entity warned that this is a serious case, since the adulterated product could put the lives of patients at risk.
This is the medicine known as MABTHERA (Rituximab) Concentrate for Infusion 500 mg/50 mLidentified with the supposed lot M8521D09with manufacturing date 09-2023 and expiration 09-2026.
“After receiving samples of the product, the holder of the health registry in Colombia, F. Hoffmann–La Roche Ltd.concluded that said batch does not exist among the authorized presentations for the country,” he said.
You may be interested in: “Something big is coming”: Yeison Jiménez released the scoop in the middle of Megaland 2025
He noted that the technical analysis also revealed visible differences in packaging, holograms, codes, printing and other security elements, which confirmed that it is a falsification.
Invima was emphatic in pointing out that this product does not guarantee quality, safety or effectiveness, and represents a critical risk because its composition and storage conditions are unknown.
This could cause treatment failure, adverse reactions severe or life-threatening complications.
“Counterfeiting of medicines constitutes a serious threat to the public health. We invite citizens to always purchase products in authorized establishments, verify the health record and report any suspicions,” he stated. William SazaInvima Pharmacovigilance coordinator.
You may be interested in: Eye! These would be the last long weekends of December
Among the recommendations are not to acquire or consume the product under the counterfeit batch, verify the authenticity of the medicines on the official portal of the Invimaimmediately suspend its use if it has already been consumed and report any adverse event through the channels of the safety program. pharmacovigilance.
The entity also urged the Health Secretariats to reinforce inspections and controls to detect illegal distribution points.
At IPS He asked them to guide the patients, suspend any administration of the adulterated product and report data on its acquisition.
Source: Integrated Information System
